Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 26, No 4 (2022)
Review paper
Published online: 2022-11-07
View PDF Download PDF file View HTML
Get Citation

The impact of sleep disorders in the formation of hypertension

Ganna Isayeva1, Anna Shalimova12, Olena Buriakovska1
DOI: 10.5603/AH.a2022.0014
·
Arterial Hypertension 2022;26(4):170-179.
Affiliations
  1. Government Institution ‘L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine', Kharkiv, Ukraine
  2. Kharkiv National Medical University, Kharkiv, Ukraine

open access

Vol 26, No 4 (2022)
REVIEW
Published online: 2022-11-07

Abstract

Hypertension is one of the most common chronic non-communicable disease in the world. Risk factors, methods of prevention and treatment of hypertension have been sufficiently studied. However scientists are still looking for pathogenetic mechanisms of its development. At the same time 36.9% of patients with hypertension had different sleep disorders. Patients with insomnia have a 21% higher risk of developing hypertension compared with those who have quality sleep. Hypnotics are given up to 15% of patients with hypertension. Hypnotics have been shown to increase the risk of cardiovascular events. 44.1% of patients with established diseases of the cardiovascular system have problems with the quality or duration of sleep. At this time, hypertension and sleep disorders are considered mutually aggravating diseases.

Abstract

Hypertension is one of the most common chronic non-communicable disease in the world. Risk factors, methods of prevention and treatment of hypertension have been sufficiently studied. However scientists are still looking for pathogenetic mechanisms of its development. At the same time 36.9% of patients with hypertension had different sleep disorders. Patients with insomnia have a 21% higher risk of developing hypertension compared with those who have quality sleep. Hypnotics are given up to 15% of patients with hypertension. Hypnotics have been shown to increase the risk of cardiovascular events. 44.1% of patients with established diseases of the cardiovascular system have problems with the quality or duration of sleep. At this time, hypertension and sleep disorders are considered mutually aggravating diseases.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

hypertension; sleep disorders; insomnia

About this article
Title

The impact of sleep disorders in the formation of hypertension

Journal

Arterial Hypertension

Issue

Vol 26, No 4 (2022)

Article type

Review paper

Pages

170-179

Published online

2022-11-07

Page views

3413

Article views/downloads

461

DOI

10.5603/AH.a2022.0014

Bibliographic record

Arterial Hypertension 2022;26(4):170-179.

Keywords

hypertension
sleep disorders
insomnia

Authors

Ganna Isayeva
Anna Shalimova
Olena Buriakovska

References (92)
  1. Legramante JM, Galante A. Sleep and hypertension: a challenge for the autonomic regulation of the cardiovascular system. Circulation. 2005; 112(6): 786–788.
    CrossRefPubMed
  2. Lombardi F, Parati G. An update on: cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. Cardiovasc Res. 2000; 45(1): 200–211.
    CrossRefPubMed
  3. Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007; 30(2): 213–218.
    CrossRefPubMed
  4. Buysse DJ. Insomnia. JAMA. 2013; 309(7): 706–716.
    CrossRefPubMed
  5. Lindberg E, Janson C, Johannessen A, et al. Sleep time and sleep-related symptoms across two generations - results of the community-based RHINE and RHINESSA studies. Sleep Med. 2020; 69: 8–13.
    CrossRefPubMed
  6. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep. 1991; 14(5): 392–398.
    PubMed
  7. Léger D, Guilleminault C, Bader G, et al. [Diurnal consequence of insomnia: impact on quality of life]. Rev Neurol (Paris). 2001; 157(10): 1270–1278.
    PubMed
  8. Ohayon MM, Smirne S. Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med. 2002; 3(2): 115–120.
    CrossRefPubMed
  9. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989; 262(11): 1479–1484.
    CrossRefPubMed
  10. Quera-Salva MA, Orluc A, Goldenberg F, et al. Insomnia and use of hypnotics: study of a French population. Sleep. 1991; 14(5): 386–391.
    CrossRefPubMed
  11. Johnson E. Epidemiology of Insomnia: from Adolescence to Old Age. Sleep Med Clin. 2006; 1(3): 305–317.
    CrossRef
  12. Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009; 32(1): 55–64.
    PubMed
  13. Khan MS, Aouad R. The Effects of Insomnia and Sleep Loss on Cardiovascular Disease. Sleep Med Clin. 2017; 12(2): 167–177.
    CrossRefPubMed
  14. Lanfranchi PA, Pennestri MH, Fradette L, et al. Nighttime blood pressure in normotensive subjects with chronic insomnia: implications for cardiovascular risk. Sleep. 2009; 32(6): 760–766.
    CrossRefPubMed
  15. Magee CA, Caputi P, Iverson DC, et al. Factors associated with short and long sleep. Prev Med. 2009; 49(6): 461–467.
    CrossRefPubMed
  16. Krueger PM, Friedman EM. Sleep duration in the United States: a cross-sectional population-based study. Am J Epidemiol. 2009; 169(9): 1052–1063.
    CrossRefPubMed
  17. Kronholm E, Härmä M, Hublin C, et al. Self-reported sleep duration in Finnish general population. J Sleep Res. 2006; 15(3): 276–290.
    CrossRefPubMed
  18. Nishitani N, Sakakibara H, Akiyama I. Short Sleeping Time and Job Stress in Japanese White-Collar Workers. Open Sleep J. 2013; 6(1): 104–109.
    CrossRef
  19. National Center for Health Statistics. Mortality multiple cause micro-data files, 2015: public-use data file and documentation: NHLBI tabulations. https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm (23 Dec 2018).
  20. Silva-Costa A, Griep RH, Rotenberg L. Associations of a Short Sleep Duration, Insufficient Sleep, and Insomnia with Self-Rated Health among Nurses. PLoS One. 2015; 10(5): e0126844.
    CrossRefPubMed
  21. Bertisch SM, Pollock BD, Mittleman MA, et al. Insomnia with objective short sleep duration and risk of incident cardiovascular disease and all-cause mortality: Sleep Heart Health Study. Sleep. 2018; 41(6).
    CrossRefPubMed
  22. Hafner M, Stepanek M, Taylor J, et al. Why Sleep Matters-The Economic Costs of Insufficient Sleep: A Cross-Country Comparative Analysis. Rand Health Q. 2017; 6(4): 11.
    PubMed
  23. Dahl RE. The consequences of insufficient sleep for adolescents: Links between sleep and emotional regulation. Phi Delta Kappan. 1999; 80: 354–359.
  24. Riemann D, Nissen C, Palagini L, et al. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015; 14(5): 547–558.
    CrossRefPubMed
  25. Ayada C, Toru Ь, Korkut Y. The relationship of stress and blood pressure effectors . Hippokratia. 2015; 19(2): 99–108.
  26. Möller-Levet C, Archer S, Bucca G, et al. Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. Proceedings of the National Academy of Sciences. 2013; 110(12): E1132–E1134.
    CrossRefPubMed
  27. Ackermann K, Plomp R, Lao O, et al. Effect of sleep deprivation on rhythms of clock gene expression and melatonin in humans. Chronobiol Int. 2013; 30(7): 901–909.
    CrossRefPubMed
  28. Kirschbaum C, Hellhammer DH. Salivary Cortisol. Encycl Stress. 2007: 405–409.
    CrossRef
  29. Vining RF, McGinley RA, Maksvytis JJ, et al. Salivary cortisol: a better measure of adrenal cortical function than serum cortisol. Ann Clin Biochem. 1983; 20 (Pt 6): 329–335.
    CrossRefPubMed
  30. Morgan E, Schumm LP, McClintock M, et al. Sleep Characteristics and Daytime Cortisol Levels in Older Adults. Sleep. 2017; 40(5).
    CrossRefPubMed
  31. Pasquali R, Vicennati V, Gambineri A, et al. Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity. Int J Obes (Lond). 2008; 32(12): 1764–1779.
    CrossRefPubMed
  32. Reinehr T, Andler W. Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm Res. 2004; 62(3): 107–112.
    CrossRefPubMed
  33. Adam TC, Hasson RE, Ventura EE, et al. Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. J Clin Endocrinol Metab. 2010; 95(10): 4729–4735.
    CrossRefPubMed
  34. Weigensberg MJ, Toledo-Corral CM, Goran MI. Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab. 2008; 93(4): 1372–1378.
    CrossRefPubMed
  35. Born J, Muth S, Fehm HL. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology. 1988; 13(3): 233–243.
    CrossRefPubMed
  36. Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996; 81(7): 2468–2473.
    CrossRefPubMed
  37. Späth-Schwalbe E, Gofferje M, Kern W, et al. Sleep disruption alters nocturnal ACTH and cortisol secretory patterns. Biol Psychiatry. 1991; 29(6): 575–584.
    CrossRefPubMed
  38. Guyon A, Balbo M, Morselli LL, et al. Adverse effects of two nights of sleep restriction on the hypothalamic-pituitary-adrenal axis in healthy men. J Clin Endocrinol Metab. 2014; 99(8): 2861–2868.
    CrossRefPubMed
  39. Rao MN, Blackwell T, Redline S, et al. Osteoporotic Fractures in Men (MrOS) Study Group. Association between sleep duration and 24-hour urine free cortisol in the MrOS Sleep Study. PLoS One. 2013; 8(9): e75205.
    CrossRefPubMed
  40. Abell JG, Shipley MJ, Ferrie JE, et al. Recurrent short sleep, chronic insomnia symptoms and salivary cortisol: A 10-year follow-up in the Whitehall II study. Psychoneuroendocrinology. 2016; 68: 91–99.
    CrossRefPubMed
  41. Pulopulos MM, Hidalgo V, Almela M, et al. Hair cortisol and cognitive performance in healthy older people. Psychoneuroendocrinology. 2014; 44: 100–111.
    CrossRefPubMed
  42. MacLullich AMJ, Deary IJ, Starr JM, et al. Plasma cortisol levels, brain volumes and cognition in healthy elderly men. Psychoneuroendocrinology. 2005; 30(5): 505–515.
    CrossRefPubMed
  43. Geerlings MI, Sigurdsson S, Eiriksdottir G, et al. Salivary cortisol, brain volumes, and cognition in community-dwelling elderly without dementia. Neurology. 2015; 85(11): 976–983.
    CrossRefPubMed
  44. MacPherson SE, Cox SR, Dickie DA, et al. Brain white matter integrity and cortisol in older men: the Lothian Birth Cohort 1936. Neurobiol Aging. 2015; 36(1): 257–264.
    CrossRefPubMed
  45. Echouffo-Tcheugui JB, Conner SC, Himali JJ, et al. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. Neurology. 2018; 91(21): e1961–e1970.
    CrossRefPubMed
  46. Bernard V, Young J, Binart N. Prolactin — a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019; 15(6): 356–365.
    CrossRefPubMed
  47. Bugge K, Papaleo E, Haxholm GW, et al. A combined computational and structural model of the full-length human prolactin receptor. Nat Commun. 2016; 7: 11578.
    CrossRefPubMed
  48. Andersen M, Glintborg D. Metabolic Syndrome in Hyperprolactinemia. Front Horm Res. 2018; 49: 29–47.
    CrossRefPubMed
  49. Chan V, Wang C, Yeung RT. Effects of heroin addiction on thyrotrophin, thyroid hormones and porlactin secretion in men. Clin Endocrinol (Oxf). 1979; 10(6): 557–565.
    CrossRefPubMed
  50. Bart G, Borg L, Schluger JH, et al. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther. 2003; 306(2): 581–587.
    CrossRefPubMed
  51. Pfeiffer A, Braun S, Mann K, et al. Anterior pituitary hormone responses to a kappa-opioid agonist in man. J Clin Endocrinol Metab. 1986; 62(1): 181–185.
    CrossRefPubMed
  52. Leadem CA, Yagenova SV. Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology. 1987; 45(2): 109–117.
    CrossRefPubMed
  53. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. Information Last Update: April 16, 2019.
  54. Nilsson L, Binart N, Bohlooly-Y M, et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005; 331(4): 1120–1126.
    CrossRefPubMed
  55. Petryk A, Fleenor D, Driscoll P, et al. Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2. J Endocrinol. 2000; 164(3): 277–286.
    CrossRefPubMed
  56. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med. 2010; 16(7): 804–808.
    CrossRefPubMed
  57. Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011; 14(3): 199–207.
    CrossRefPubMed
  58. Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Prim Care Diabetes. 2016; 10(1): 60–65.
    CrossRefPubMed
  59. Ruiz-Herrera X, de Los Ríos EA, Díaz JM, et al. Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males. Endocrinology. 2017; 158(1): 56–68.
    CrossRefPubMed
  60. Wang T, Lu J, Xu Yu, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013; 36(7): 1974–1980.
    CrossRefPubMed
  61. Zhang L, Curhan GC, Forman JP. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens. 2010; 28(7): 1400–1405.
    CrossRefPubMed
  62. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 2009; 54(1): 98–105.
    CrossRefPubMed
  63. Haring R, Friedrich N, Völzke H, et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2014; 35(18): 1215–1221.
    CrossRefPubMed
  64. Friedrich N, Rosskopf D, Brabant G, et al. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes. 2010; 118(4): 266–273.
    CrossRefPubMed
  65. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008; 29(1): 1–41.
    CrossRefPubMed
  66. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol. 1997; 153(3): 423–428.
    CrossRefPubMed
  67. Haring R, Völzke H, Vasan RS, et al. Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP). Atherosclerosis. 2012; 221(2): 570–576.
    CrossRefPubMed
  68. Balbach L, Wallaschofski H, Völzke H, et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013; 13: 12.
    CrossRefPubMed
  69. Daimon M, Kamba A, Murakami H, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One. 2017; 12(4): e0175204.
    CrossRefPubMed
  70. Sayk F, Teckentrup C, Becker C, et al. Effects of selective slow-wave sleep deprivation on nocturnal blood pressure dipping and daytime blood pressure regulation. Am J Physiol Regul Integr Comp Physiol. 2010; 298(1): R191–R197.
    CrossRefPubMed
  71. Gonzaga C, Bertolami A, Bertolami M, et al. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015; 29(12): 705–712.
    CrossRefPubMed
  72. Kronholm E, Härmä M, Hublin C, et al. Self-reported sleep duration in Finnish general population. J Sleep Res. 2006; 15(3): 276–290.
    CrossRefPubMed
  73. Gottlieb DJ, Redline S, Nieto FJ, et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep. 2006; 29(8): 1009–1014.
    CrossRefPubMed
  74. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006; 47(5): 833–839.
    CrossRefPubMed
  75. Knutson KL, Van Cauter E, Rathouz PJ, et al. Association between sleep and blood pressure in midlife: the CARDIA sleep study. Arch Intern Med. 2009; 169(11): 1055–1061.
    CrossRefPubMed
  76. Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. J Sleep Res. 1999; 8(3): 175–183.
    CrossRefPubMed
  77. Cappuccio FP, Stranges S, Kandala NB, et al. Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. Hypertension. 2007; 50(4): 693–700.
    CrossRefPubMed
  78. Haack M, Serrador J, Cohen D, et al. Increasing sleep duration to lower beat-to-beat blood pressure: a pilot study. J Sleep Res. 2013; 22(3): 295–304.
    CrossRefPubMed
  79. Lusardi P, Mugellini A, Preti P, et al. Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects. Am J Hypertens. 1996; 9(5): 503–505.
    CrossRefPubMed
  80. Tochikubo O, Ikeda A, Miyajima E, et al. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension. 1996; 27(6): 1318–1324.
    CrossRefPubMed
  81. Dettoni JL, Consolim-Colombo FM, Drager LF, et al. Cardiovascular effects of partial sleep deprivation in healthy volunteers. J Appl Physiol (1985). 2012; 113(2): 232–236.
    CrossRefPubMed
  82. Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep. 2010; 33(9): 1159–1164.
    CrossRefPubMed
  83. Innes KE, Selfe TK, Agarwal P. Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic review. Sleep Med Rev. 2012; 16(4): 309–339.
    CrossRefPubMed
  84. Ulfberg J, Nyström B, Carter N, et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001; 16(6): 1159–1163.
    CrossRefPubMed
  85. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med. 2006; 7(7): 545–552.
    CrossRefPubMed
  86. Lindner A, Fornadi K, Lazar AS, et al. Periodic limb movements in sleep are associated with stroke and cardiovascular risk factors in patients with renal failure. J Sleep Res. 2012; 21(3): 297–307.
    CrossRefPubMed
  87. Mirza M, Shen WK, Sofi A, et al. Frequent periodic leg movement during sleep is associated with left ventricular hypertrophy and adverse cardiovascular outcomes. J Am Soc Echocardiogr. 2013; 26(7): 783–790.
    CrossRefPubMed
  88. Banegas JR, Navarro-Vidal B, Ruilope LM, et al. Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment. Circ Cardiovasc Qual Outcomes. 2015; 8(1): 67–76.
    CrossRefPubMed
  89. Ghazi L, Bennett A, Petrov ME, et al. Over-the-counter and prescription sleep medication and incident stroke: the REasons for Geographic and Racial Differences in Stroke study. J Stroke Cerebrovasc Dis. 2014; 23(8): 2110–2116.
    CrossRefPubMed
  90. Hernández-Aceituno A, Guallar-Castillón P, García-Esquinas E, et al. Association between sleep characteristics and antihypertensive treatment in older adults. Geriatr Gerontol Int. 2019; 19(6): 537–540.
    CrossRefPubMed
  91. Tanabe N, Fujita T, Fujii Y, et al. Investigation of the Factors that Contribute to the Onset of Insomnia in Hypertensive Patients by Using a Post-marketing Surveillance Database. Yakugaku Zasshi. 2011; 131(5): 669–677.
    CrossRef
  92. Samizo K, Kawabe E, Hinotsu S, et al. Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: a pilot study of prescription-event monitoring in Japan. Drug Saf. 2002; 25(11): 811–821.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl